CLINICAL ROLE -
First-Line Immunotherapy Combo Fails to Improve Survival in Lung Cancer Trial
Durvalumab plus tremelimumab did not meet the primary endpoint of the phase 3 MYSTIC trial evaluating improvement in overall survival and progression-free survival compared with chemotherapy.
Read More
Trending News Today: FDA Panel Recommends Co-prescribing Naloxone with Painkillers
Top news of the day across the health care landscape.
Disparities Found in HIV Prevention Among Different Groups of Black Women
Foreign-born black women aren’t benefiting from HIV prevention programs at the same rates as other women.
Schizophrenia: Quality of Care & Relapse Prevention
Watch
Emerging Therapies & Strategies in Schizophrenia
Improving Resistance to Use LAI Therapy in Schizophrenia
LAI Antipsychotics in Schizophrenia: Clinician's Role
LAI Antipsychotics in Schizophrenia: Tolerability
LAI Antipsychotics: Treatment Selection in Schizophrenia
LAI Antipsychotics: Establishing a Treatment Plan
Underutilization of LAI Antipsychotics in Schizophrenia
Effects of Schizophrenia Relapse on Hospitalization
Preventing Relapses in Schizophrenia
Consequences of Relapses in Schizophrenia
Predictors of Relapse in Schizophrenia
Current Challenges in the Treatment of Schizophrenia
Optimal Treatment of Schizophrenia: Take-Home Messages
Overcoming Obstacles to LAIs in Schizophrenia Management
Schizophrenia: Switching to a Long-Acting Injectable
Benefit of Long Acting Injectables in Schizophrenia
Adherence to Oral Agents in Schizophrenia Management
Schizophrenia: Understanding the Impact of Adherence
Schizophrenia: Consequences of Multiple Relapses
Importance of Relapse Prevention in Schizophrenia
Unmet Needs and Challenges in Managing Schizophrenia
Partnership Designed to Improve Medication Adherence Among Patients with Type 2 Diabetes
The program launched by the Baltimore-based organizations is the first of its kind to leverage video technology and a public health practice known as Directly Observed Therapy, or DOT.
In the Age of the Drone, Are You a Dinosaur?
In 2019, you can change your destiny, or you can maintain the status quo. You have a choice: become a drone or remain a dinosaur.
Treatment for Chronic Idiopathic Constipation Receives FDA Approval
Prucalopride (Motegrity, Shire) is the only serotonin-4 receptor agonist approved for adults with Chronic Idiopathic Constipation.
FDA Approves New Drug for Chronic Idiopathic Constipation
Prucalopride (Motegrity, Shire) is the only serotonin-4 receptor agonist approved for adults with chronic idiopathic constipation.
Flu Vaccination Reminders Prove Effective for Patients With Diabetes
Influenza vaccinations among patients with diabetes rose by 20% when they were notified about scheduling their flu shot, according to a new study.